



Press Release |

The IBA IntegraLab team supports PET centers to be compliant with the new FDA regulations

Louvain-la-Neuve, Belgium, May 26th, 2011 – IBA (Ion Beam Applications S.A.) announced today, that its IntegraLab[®] team is supporting PET centers to be compliant with FDA regulations.

Based on its longstanding experience in setting-up cGMP and GMP (Europe) radiopharmacies, the IBA IntegraLab team of experts is already supporting American PET centers to comply with the new FDA regulations. Following December 12th, 2011, producers of PET drugs intended for commercial use will be required to follow the manufacturing requirements as specified in Part 212 of Title 21 of the Code of Federal Regulations.

The IntegraLab[®] solution combines equipment and services allowing the establishment of research or of a radiopharmaceutical production center whilst achieving full regulatory compliance. In addition to our team of experts, the IBA experience in the fields of PET distribution as well as PET centers validation around the world (with over 50 centers worldwide) has allowed us to set up many fully compliant GMP PET & SPECT centers.

Therefore, the IBA Integralab[®] team is looking forward to supporting your existing PET center with consultancy visits and advice in order to assess the compliance to the new FDA regulations.

To benefit from IBA's support, do stop by the IBA booth #7059 during SNM annual meeting in San Antonio, TX or send an e-mail to info-cyclo@iba-group.com

About IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.

IBA Molecular's division is the only global provider of PET radiopharmaceuticals. We have leveraged our global expertise and innovation to maximize our customers' access to the most reliable radiopharmaceutical distribution network, the most advanced cyclotron solutions and the most novel research radionuclides. With our focus on Protecting, Enhancing and Saving Lives, we are committed to ensuring that our customers' ability to properly care for their patients is not compromised by their access to vital radiopharmaceuticals

Website: <http://www.iba-cyclotronolutions.com>.

Contact

Pablo Veiga Torres
Sales Manager, United States and Latin America

IBA

Cell: +1 954 562 7693

Email : Pablo.veiga@iba-group.com